


factors must be considered when choosing therapies for women of child-bearing age. Immunosuppressive agents also can be associated with bone marrow suppression and with additional long-term risks such as malignancy.

### Acknowledgments

The author wishes to acknowledge the assistance of Kathleen Maksimowicz-McKinnon, MD and Kelly Liang, MD.

 *For a deeper discussion on this topic, please see Chapter 270, "The Systemic Vasculitides," in Goldman-Cecil Medicine, 25th Edition.*

### SUGGESTED READINGS

Bloch DA, Michel BA, Hunder GG, et al: The American College of Rheumatology 1990 criteria for the classification of vasculitis: patients and methods, *Arthritis Rheum* 33:1068–1073, 1990.

Hoffman GS, Cid MC, Rendt-Zagar KE, et al: Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial, *Ann Intern Med* 146:621–630, 2007.

Hunder GG, Bloch DA, Michel BA, et al: The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis, *Arthritis Rheum* 33:1122–1128, 1990.

Jennette JC, Falk RJ, Andrassy K, et al: Nomenclature of systemic vasculitides: proposal of an international consensus conference, *Arthritis Rheum* 37:187–192, 1994.

Jones RB, Tervaert JW, Hauser T, et al: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis, *N Engl J Med* 363:211–220, 2010.

Specks U, Merkel PA, Seo P, et al: Efficacy of remission-induction regimens for ANCA-associated vasculitis, *N Engl J Med* 369:417–427, 2013.

Stone JH, Merkel PA, Spiera R, et al: Rituximab versus cyclophosphamide for ANCA-associated vasculitis, *N Engl J Med* 363:221–232, 2010.

Weiss PF: Pediatric vasculitis, *Pediatr Clin North Am* 59:407–423, 2012.